A Phase 3 trial found AstraZeneca's () experimental lung cancer drug datopotamab deruxtecan (Dato-DXd) did not significantly improve patients' overall survival rates.

The results from the TROPION-Lung01 trial showed the overall survival rate "did not reach statistical significance" in patients with metastatic non-small cell lung cancer, the company said.

AstraZeneca jointly developed the drug with Japan's Daiichi Sankyo.

Drug Was Aimed at Trea🌺ting Non-Small Cell Lung Cancer

 “Despite many efforts to surpass docetaxel with novel approaches in previously treated advanced or metastatic non-small cell lung cancer, patients only survive for about one year," Jacob Sands of the Dana-Farber Cancer Institute and investigator in the trial said.

Docetaxel is the current sꦍtandard of chemotherapy for adults with advanced or metastatic nonsquamous non-sma🍰ll cell lung cancer.

AstraZeneca shares initially fell following the news Tuesday, before rebounding later in the session. They were little changed at $80.96 as of 11:45 a.m. ET and have gained over 20% since the beginning of the year.